Recombinant Zebrafish ANKHA

• Cat.No.: ANKHA-3339Z
• Product Overview: Recombinant Zebrafish ANKHA full length or partial length protein was expressed.

Specification

• Source: Mammalian Cells
• Species: Zebrafish
• Tag: His
• Form: Liquid or lyophilized powder
• Endotoxin: < 1.0 eu per μg of the protein as determined by the LAL method.
• Purity: >80%
• Notes: This item requires custom production and lead time is between 5-9 weeks. We can custom produce according to your specifications.
• Storage: Store it at +4 oC for short term. For long term storage, store it at -20 oC～-80 oC.
• Storage Buffer: PBS buffer

Gene Information

• Gene Name: ankha ANKH inorganic pyrophosphate transport regulator a [ Danio rerio (zebrafish) ]
• Official Symbol: ANKHA
• Gene ID: 571148
• mRNA Refseq: NM_001030259
• Protein Refseq: NP_001025430
• UniProt ID: F1Q528

Reviews

09/08/2021

This reliability reduces experimental variability and enhances the accuracy of data interpretation.

06/03/2021

Their technical expertise and experience in the field allow them to provide invaluable guidance and assistance.

03/09/2020

They can offer insights on experimental design, optimal usage protocols, and troubleshoot any challenges that may arise during the course of the trial.

08/27/2017

Its potency and specificity make it a valuable tool for studying specific biological pathways or mechanisms.

Q&As

Is the ANKHA protein present only in humans, or is it found in other species as well?

The ANKHA protein is not exclusive to humans. It is highly conserved among vertebrates, meaning that it is found in other species as well. Orthologs of the ANKHA protein, with similar functions and structures, have been identified in various organisms, including mammals, birds, reptiles, and fish.

Are there any diseases or conditions associated with ANKHA protein mutations?

Yes, mutations in the ANKHA gene have been associated with a rare hereditary disorder called familial chondrocalcinosis, also known as calcium pyrophosphate deposition disease (CPPD). In this condition, there is an abnormal accumulation of calcium pyrophosphate crystals in the joints, leading to inflammation, pain, and joint damage.

How common are ANKHA gene mutations in familial chondrocalcinosis?

ANKHA gene mutations are rare in the general population. However, specific mutations in the gene have been identified in individuals with familial chondrocalcinosis. The prevalence of ANKHA gene mutations in this condition varies depending on the population studied.

Are there any animal models or cell culture studies used to investigate ANKHA protein function?

Yes, researchers have utilized animal models, such as mice and zebrafish, to study ANKHA protein function and associated diseases. By genetically modifying these animals or inducing targeted mutations in the ANKHA gene, scientists can investigate the effects of ANKHA dysfunction on skeletal and joint health. Additionally, cell culture studies using human and animal cell lines have been employed to investigate ANKHA protein function and its interaction with other molecular components involved in mineralization processes.

Is there ongoing research on ANKHA protein and its associated diseases?

Yes, research is ongoing to better understand the role of the ANKHA protein in mineralization processes and its implications for disease development. Scientists are investigating potential therapeutic strategies that target ANKHA function, such as identifying compounds that can modulate PPi levels or studying gene therapy approaches to correct ANKHA gene mutations. However, it's important to note that research in this area is still in the early stages, and more studies are needed to develop effective treatments.

Can ANKHA gene mutations also cause other diseases or conditions?

While ANKHA gene mutations are primarily associated with familial chondrocalcinosis, mutations in other genes involved in pyrophosphate metabolism or joint health may also contribute to the development of related disorders. For example, mutations in the ANKH gene are associated with a condition called familial calcium pyrophosphate dihydrate deposition (CPPD) syndrome, which shares some similarities with familial chondrocalcinosis.

Are there any therapeutic interventions or lifestyle changes that can help individuals with ANKHA-related diseases?

Currently, there are no specific therapeutic interventions targeted at correcting ANKHA gene mutations or directly modulating ANKHA protein function. However, lifestyle modifications can be beneficial for managing symptoms and promoting joint health. These may include maintaining a healthy weight, engaging in regular exercise that is suitable for the individual's condition, and using assistive devices or orthotics to support joints. Additionally, prompt treatment of acute flare-ups with pain relief medications and anti-inflammatory drugs can help manage symptoms.

Can variations or polymorphisms in the ANKHA gene affect an individual's susceptibility to diseases?

There is ongoing research investigating the association between ANKHA gene variations and the susceptibility to certain diseases. Some studies have suggested that specific polymorphisms in the ANKHA gene may be associated with an increased risk of developing CPPD-related conditions or other joint disorders. However, more research is needed to confirm these associations and understand the precise impact of ANKHA gene variations on disease susceptibility.

How long has the ANKHA protein and its associated diseases been studied?

Research on the ANKHA protein and its associated diseases is a relatively recent development. The identification of ANKHA gene mutations in familial chondrocalcinosis and CPPD-related conditions occurred in the late 1990s and early 2000s. Since then, studies have been conducted to understand the protein's function, regulation, and its implications for disease development. Ongoing research continues to deepen our understanding of ANKHA-related diseases and explore potential therapeutic strategies.

Are there any specific therapeutic approaches targeting ANKHA-related diseases?

Currently, there are no specific therapeutic approaches targeting ANKHA-related diseases. The treatment primarily focuses on managing symptoms and slowing disease progression. This may include the use of nonsteroidal anti-inflammatory drugs (NSAIDs), analgesics, physical therapy, and, in severe cases, joint replacement surgery.